Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J SCHAAF

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Cancer Chemotherapy and Pharmacology|September 24, 2009
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumorsBhuvaneswari Ramaswamy, Tanios Bekaii-Saab, Larry J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumorsL B Saltz, D Spriggs, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disordersThomas S Lin, Kristie A Blum, Diane Beth Fischer, et al.
JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2005
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumorsHenry C Pitot, Alex A Adjei, Joel M Reid, et al.
Haematologica|May 13, 2010
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemiasWilliam Blum, Mitch A Phelps, Rebecca B Klisovic, et al.
Journal of Cachexia, Sarcopenia and Muscle|February 16, 2026
Loss of Myonuclei and Transcriptional Activity During Diaphragm Atrophy in Critically Ill PatientsWout J Claassen, Marloes van den Berg, Zhong Hua Shi, et al.
Stem Cell Reports|May 8, 2018
Large-Scale Expansion of Human iPSC-Derived Skeletal Muscle Cells for Disease Modeling and Cell-Based Therapeutic StrategiesErik van der Wal, Pablo Herrero-Hernandez, Raymond Wan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2000
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patientsJ G Slatter, L J Schaaf, J P Sams, et al.
Clinical Pharmacology and Therapeutics|May 1, 2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analysesM A Phelps, T E Stinchcombe, J S Blachly, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Cancer Chemotherapy and Pharmacology|September 24, 2009
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumorsBhuvaneswari Ramaswamy, Tanios Bekaii-Saab, Larry J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 1998
Phase I clinical and pharmacologic study of weekly cisplatin combined with weekly irinotecan in patients with advanced solid tumorsL B Saltz, D Spriggs, L J Schaaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disordersThomas S Lin, Kristie A Blum, Diane Beth Fischer, et al.
JCO Precision Oncology|February 9, 2022
Phase I Trial of Dabrafenib and Pazopanib in <i>BRAF</i> Mutated Advanced MalignanciesSigurdis Haraldsdottir, Filip Janku, Ming Poi, et al.
Cancer Chemotherapy and Pharmacology|December 6, 2005
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumorsHenry C Pitot, Alex A Adjei, Joel M Reid, et al.
Haematologica|May 13, 2010
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemiasWilliam Blum, Mitch A Phelps, Rebecca B Klisovic, et al.
Journal of Cachexia, Sarcopenia and Muscle|February 16, 2026
Loss of Myonuclei and Transcriptional Activity During Diaphragm Atrophy in Critically Ill PatientsWout J Claassen, Marloes van den Berg, Zhong Hua Shi, et al.
Stem Cell Reports|May 8, 2018
Large-Scale Expansion of Human iPSC-Derived Skeletal Muscle Cells for Disease Modeling and Cell-Based Therapeutic StrategiesErik van der Wal, Pablo Herrero-Hernandez, Raymond Wan, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 22, 2000
Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patientsJ G Slatter, L J Schaaf, J P Sams, et al.
Clinical Pharmacology and Therapeutics|May 1, 2014
Erlotinib in African Americans with advanced non-small cell lung cancer: a prospective randomized study with genetic and pharmacokinetic analysesM A Phelps, T E Stinchcombe, J S Blachly, et al.
Pageof 10